Pharmaceuticals & Therapeutics

The Virginia-based startup landed a major funding round to automate liquid biopsy sample prep, aiming to make cancer detection faster and more reliable.

A biotech firm says it has grown functional human sperm in a lab and created embryos, a huge leap that could change millions of lives and spark ethical debate.

From malaria vaccines to maglev trains, 12 finalists are celebrated for breakthroughs tackling the world's most pressing environmental and health crises.

A new study reveals Efsubaglutide Alfa not only controls diabetes but may also improve the body's own insulin-producing cells, heralding a new era.

The 2026 Giants of Multiple Sclerosis® awards celebrate the multidisciplinary teams shaping the future of MS, from research to rehabilitation.

After two rejections and a dramatic financial restructuring, Atara Biotherapeutics has a clear path to resubmit its key cancer therapy to the FDA.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.

A new strategic alliance brings European cGMP-grade vitamin APIs to the U.S., promising to enhance quality and supply reliability for compounding pharmacies.

From nano-surfactants to pharmaceuticals, SureNano Science is betting its future on a novel obesity drug. Can this microcap survive the big leagues?

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

Response Pharmaceuticals unveils promising data on RDX-002, a first-in-class drug aimed at preventing a severe side effect of essential mental health drugs.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.

A new report reveals that equipment fires, regulatory hurdles, and subtle operational flaws are emerging as major threats to the clean energy transition.

A new specialty clinic in Philadelphia tackles a nationwide shortage of pet dentists, offering advanced, team-based oral care for common animal ailments.

With demand for blood and plasma soaring, Canadian Blood Services is betting on national pride to solve a critical shortage. But can a new campaign work?

Biotech firm AstronauTx appoints a new CMO and VP, signaling a pivotal move to clinical trials for its novel Alzheimer's therapy targeting sleep architecture.

Javier Vasquez of Miguel's Restaurants joins the LLUCH Foundation board, blending a 50-year family legacy with a new era of strategic philanthropy.

With two pivotal trial readouts looming and cash projected to last only into Q4, Tvardi Therapeutics faces a make-or-break year for its STAT3 inhibitors.

As Talphera preps its Q1 update, all eyes are on its breakthrough drug Niyad® and the mounting costs of bringing a potential game-changer to market.

After 40 years, capsule giant CapsCanada becomes Lyfe Group, a strategic move to unify its brand, leverage new investments, and lead the drug delivery market.